User profiles for Miltiades Kyprianou

Miltiades Kyprianou

Independent Scientific Investigator
Verified email at sepsis.gr
Cited by 2794

[HTML][HTML] Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 …

…, A Kotsaki, MG Netea, J Eugen-Olsen, M Kyprianou… - Nature medicine, 2021 - nature.com
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …

[HTML][HTML] Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis

…, T Huet, G Cavalli, A Gori, M Kyprianou… - The Lancet …, 2021 - thelancet.com
Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …

[HTML][HTML] The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis

A Arida, M Kyprianou, M Kanakis… - BMC Musculoskeletal …, 2010 - Springer
Background Ultrasonography of temporal arteries is not commonly used in the approach of
patients with suspected giant cell arteritis (GCA) in clinical practice. A meta-analysis of …

An open label trial of anakinra to prevent respiratory failure in COVID-19

…, N Vechlidis, C Avgoustou, S Chalvatzis, M Kyprianou… - Elife, 2021 - elifesciences.org
Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR ≥6 ng/ml …

Coronavirus disease 2019 as cause of viral sepsis: a systematic review and meta-analysis

…, EJ Giamarellos-Bourboulis, M Kyprianou… - Critical care …, 2021 - journals.lww.com
Objective: Coronavirus disease 2019 is a heterogeneous disease most frequently causing
respiratory tract infection, which can induce respiratory failure and multiple organ dysfunction …

Procalcitonin to reduce long-term infection-associated adverse events in sepsis. A randomized trial

…, V Kolonia, T Gkavogianni, M Kyprianou… - American Journal of …, 2021 - atsjournals.org
Rationale: Although early antimicrobial discontinuation guided by procalcitonin (PCT) has
shown decreased antibiotic consumption in lower respiratory tract infections, the outcomes in …

[PDF][PDF] Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial

…, JWM van der Meer, G Dimopoulos, M Kyprianou… - Cell Reports …, 2022 - cell.com
The state of immune activation may guide targeted immunotherapy in sepsis. In a double-blind,
double-dummy randomized clinical study, 240 patients with sepsis due to lung infection, …

[HTML][HTML] Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome

…, M Bristianou, T Kanni, K Sereti, MA Kyprianou… - Critical Care, 2013 - Springer
Introduction The aim of this study was to investigate the kinetics of immunoglobulin M (IgM)
during the different stages of sepsis. Methods In this prospective multicenter study, blood …

Evidence for differences in men's and women's volleyball games based on skills effectiveness in four consecutive olympic tournaments

…, I Aggelonidis, A Laios, M Kyprianou - Comprehensive …, 2015 - journals.sagepub.com
This study compares the differences in effectiveness of the five volleyball skills (serve,
reception, attack, block, and dig) between men and women in high-level tournament games …

Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial

…, N Antonakos, A Safarika, M Kyprianou… - The Lancet …, 2024 - thelancet.com
Background Addition of macrolide antibiotics to β-lactam antibiotics for the treatment of patients
in hospital with community-acquired pneumonia is based on results from observational …